HealthEquity (NASDAQ:HQY) Releases Quarterly Earnings Results, Beats Estimates By $0.16 EPS

HealthEquity (NASDAQ:HQY) posted its earnings results on Tuesday. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.16, RTT News reports. The firm had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same quarter last year, the company earned $0.80 earnings per share. HealthEquity updated its FY 2026 guidance to 3.610-3.78 EPS.

HealthEquity Stock Performance

Shares of HQY opened at $113.06 on Thursday. HealthEquity has a 12-month low of $65.01 and a 12-month high of $116.00. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. The company has a market cap of $9.78 billion, a PE ratio of 103.72, a price-to-earnings-growth ratio of 1.60 and a beta of 0.45. The stock has a 50-day moving average price of $90.51 and a 200-day moving average price of $97.67.

Insider Buying and Selling

In other HealthEquity news, EVP Michael Henry Fiore sold 8,881 shares of the business’s stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the transaction, the executive vice president now owns 56,655 shares of the company’s stock, valued at $4,433,820.30. The trade was a 13.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total transaction of $446,487.50. Following the sale, the director now owns 84,969 shares in the company, valued at approximately $6,597,842.85. This trade represents a 6.34% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada lifted their price target on HealthEquity from $112.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday. Wells Fargo & Company increased their price objective on HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. The Goldman Sachs Group lifted their target price on HealthEquity from $94.00 to $104.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Barrington Research reiterated an “outperform” rating and set a $112.00 price target on shares of HealthEquity in a research report on Friday, April 11th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $115.82.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.